Novozymes A/S (OTCMKTS:NVZMY) Issues Quarterly Earnings Results, Misses Expectations By $0.44 EPS

Novozymes A/S (OTCMKTS:NVZMY) announced its earnings results on Wednesday. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.79 by ($0.44), Zacks reports. Novozymes A/S had a net margin of 13.96% and a return on equity of 6.38%. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.22 billion.

Novozymes A/S Price Performance

Shares of Novozymes A/S stock opened at $58.53 on Friday. The stock has a market capitalization of $27.41 billion, a price-to-earnings ratio of 41.81, a PEG ratio of 1.07 and a beta of 1.10. Novozymes A/S has a twelve month low of $53.95 and a twelve month high of $75.99. The company has a current ratio of 1.61, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26. The business’s 50 day simple moving average is $62.80 and its 200-day simple moving average is $62.64.

Novozymes A/S Company Profile

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).